-Live Mint The prime source of financing will be from general taxation or public exchequer, says Planning Commission Government-run hospitals may stop charging for primary services such as investigative tests as India attempts to provide universal health coverage to all its citizens. “No fee of any kind would be levied on primary healthcare services with the prime source of financing being from general taxation/public exchequer,” the Planning Commission says in its latest health...

-Outlook Nobel laureate Joseph E. Stiglitz is one of the world’s leading economists. A former chief economist at the World Bank and currently University Professor at the Columbia Business School, he was recently in India to attend an international conference on development and to promote his new book, The Price of Inequality. He spoke to Pranay Sharma about growing inequality in the world and the challenges facing India. Excerpts: * Your coinage,...

-The Times of India Medicines in India may not be sold under brand names in the near future. In its biggest move to push generic drugs and do away with brand names, the Union health ministry has ordered states to stop issuing licence for the manufacture or sale of drugs on the basis of their brand name. All pharmaceutical firms applying for licence to market or manufacture fixed dose combination (FDC) drugs will...

-Live Mint Incidents at Bhopal and Indore highlight irregularities and ethical violations in some trials In 2004, doctors at the Bhopal Memorial Hospital and Research Centre (BMHRC), established exclusively for treating the victims of the 1984 gas leak, recruited unsuspecting survivors for clinical trials without their knowledge or consent; 14 participants died during the course of the trials. Together with the episode in Indore’s Maharaja Yashwantrao Hospital (that Mint reported on 10...

-Live Mint The first in a two-part series examining the opaque world of clinical trials in India  A hospital in Indore has been able to get away with unethical medical trials in which 32 people have died over five years, according to the state government. This despite several investigations, a state government ban and Supreme Court strictures—a classic example of the lawless nature of the clinical trial business in India.   Lata Mehra, who...